BioRestorative Therapies Holds Annual Meeting Vote

TL;DR

BRTX held its annual shareholder vote on Sept 18th. Details TBD.

AI Summary

BioRestorative Therapies, Inc. filed an 8-K on September 25, 2025, reporting on matters submitted to a vote of its security holders. The filing indicates that the company held its annual meeting vote on September 18, 2025. The specific details of the vote outcomes or proposals are not detailed in this excerpt.

Why It Matters

This filing confirms that BioRestorative Therapies, Inc. has conducted its annual shareholder vote, a routine but important corporate governance event.

Risk Assessment

Risk Level: low — This is a routine corporate governance filing confirming a shareholder vote occurred, with no immediate financial or operational risks indicated.

Key Players & Entities

• BioRestorative Therapies, Inc. (company) — Registrant
• September 18, 2025 (date) — Date of earliest event reported / Annual meeting vote date
• September 25, 2025 (date) — Date of Report
• Nevada (jurisdiction) — State of incorporation
• 40 Marcus Drive Melville, New York 11747 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value BRTX NASDAQ Capital Marke

Filing Documents

• brt91825.htm (8-K) — 35KB
• 0001021771-25-000131.txt ( ) — 160KB
• brtx-20250918.xsd (EX-101.SCH) — 4KB
• brtx-20250918_lab.xml (EX-101.LAB) — 21KB
• brtx-20250918_pre.xml (EX-101.PRE) — 16KB
• brt91825_htm.xml (XML) — 4KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders On September 18, 2025, BioRestorative Therapies, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders: (i) elected the nominees as the Class II directors, (ii) approved an amendment to the Company's 2021 Stock Incentive Plan (the "Plan") to increase the number of shares of common stock authorized to be issued pursuant to the Plan from 6,850,000 to 9,850,000, (iii) ratified the selection of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, and (iv) approved, on a non-binding advisory basis, the compensation of the Company's executive officers. The following is a listing of the votes cast for or withheld, and the number of broker non-votes, with respect to the nominees for Class II directors and a listing of the votes cast for and against, as well as abstentions and broker non-votes, with respect to the other matters voted upon at the Annual Meeting, as applicable. 1. Election of Class II Directors: Number of Shares For Withheld Broker Non-Votes Francisco Silva 1,591,913 73,999 3,328,582 David Rosa 1,473,937 191,975 3,328,582 2. Approval of amendment to the Company's 2021 Stock Incentive Plan: For 1,340,653 Against 289,308 Abstentions 35,951 Broker Non-Votes 3,328,582 3. Ratification of the selection of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025: For 4,718,630 Against 271,000 Abstentions 4,864 4. Approval, on a non-binding advisory basis, of the compensation of the Company's executive officers: For 1,539,396 Against 106,661 Abstentions 19,855 Broker Non-Votes 3,328,582

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIORESTORATIVE THERAPIES, INC. Dated: September 25, 2025 By: /s/ Robert Kristal Robert Kristal Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR